The Phase 3 TEMPO-3 trial demonstrates that tavapadon, a selective D1/D5 agonist, significantly increases 'good-on-time' and reduces 'off-time' in Parkinson’s patients with motor fluctuations, offering a favorable safety profile compared to traditional D2/D3 agonists.